Screener
Protagonist Therapeutics PTGX Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $162.85M+568% | $3.78M+132% | -$44.38M-134% | -$39.34M-18.5% | -$34.77M-13.6% | ||
| $397K+30.6% | $407K+70.3% | $376K+219% | $361K+56.3% | $304K+26.1% | ||
| $14.04M+28.6% | $14.52M+5.2% | $10.7M+17.7% | $10.56M+3.9% | $10.91M+22.0% | ||
| $219.05M— | -$48.94M-139% | —— | —— | —— | ||
| $168K-79.3% | $215K-60.6% | $144K-53.5% | $88K-88.6% | $813K+2,804% | ||
| —— | $90.89M+196% | —— | -$58.56M+71.9% | —— | ||
| $9.74M+233% | $23.37M+104% | $2.84M-29.6% | $5.66M-53.0% | $2.93M+13.7% | ||
| $226.37M+682% | $65.32M+54.0% | $14.68M+143% | —— | $28.96M-84.2% | ||
| $218.88M— | -$49.16M-139% | —— | —— | —— |
FAQ
- Where does Protagonist Therapeutics's cash flow data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
